1-12 of 12
David J. Stewart
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non–Small Cell Lung Cancer Patients

Razelle Kurzrock, David J. Stewart
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (5): 1137–1148.
https://doi.org/10.1158/1078-0432.CCR-16-1968
Published: 28 February 2017
View article titled, Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non–Small Cell Lung Cancer Patients
Open the PDF for Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non–Small Cell Lung Cancer Patients in another window
Journal Articles

The Urgent Need for Clinical Research Reform to Permit Faster, Less Expensive Access to New Therapies for Lethal Diseases

David J. Stewart, Gerald Batist, Hagop M. Kantarjian, John-Peter Bradford, Joan H. Schiller, Razelle Kurzrock
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (20): 4561–4568.
https://doi.org/10.1158/1078-0432.CCR-14-3246
Published: 14 October 2015
View article titled, The Urgent Need for Clinical Research Reform to Permit Faster, Less Expensive Access to New Therapies for Lethal Diseases
Open the PDF for The Urgent Need for Clinical Research Reform to Permit Faster, Less Expensive Access to New Therapies for Lethal Diseases in another window
Journal Articles

U.S. Food and Drug Administration Inspections of Clinical Investigators: Overview of Results from 1977 to 2009

Sonia K. Morgan-Linnell, David J. Stewart, Razelle Kurzrock
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (13): 3364–3370.
https://doi.org/10.1158/1078-0432.CCR-13-3206
Published: 30 June 2014
View article titled, U.S. Food and Drug Administration Inspections of Clinical Investigators: Overview of Results from 1977 to 2009
Open the PDF for U.S. Food and Drug Administration Inspections of Clinical Investigators: Overview of Results from 1977 to 2009 in another window
Includes: Supplementary data
Journal Articles

Comprehensive Biomarker Analysis and Final Efficacy Results of Sorafenib in the BATTLE Trial

George R. Blumenschein, Jr, Pierre Saintigny, Suyu Liu, Edward S. Kim, Anne S. Tsao, Roy S. Herbst, Christine Alden, J. Jack Lee, Ximing Tang, David J. Stewart, Merrill S. Kies, Frank V. Fossella, Hai T. Tran, L. Mao, Marshall E. Hicks, Jeremy Erasmus, Jr, Sanjay Gupta, Luc Girard, Michael Peyton, Lixia Diao, Jing Wang, Suzanne E. Davis, John D. Minna, Ignacio Wistuba, Waun K. Hong, John V. Heymach, Scott M. Lippman
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (24): 6967–6975.
https://doi.org/10.1158/1078-0432.CCR-12-1818
Published: 16 December 2013
View article titled, Comprehensive Biomarker Analysis and Final Efficacy Results of Sorafenib in the BATTLE Trial
Open the PDF for Comprehensive Biomarker Analysis and Final Efficacy Results of Sorafenib in the BATTLE Trial in another window
Includes: Supplementary data
Journal Articles

EZH2 Protein Expression Associates with the Early Pathogenesis, Tumor Progression, and Prognosis of Non–Small Cell Lung Carcinoma

Carmen Behrens, Luisa M. Solis, Heather Lin, Ping Yuan, Ximing Tang, Humam Kadara, Erick Riquelme, Hector Galindo, Cesar A. Moran, Neda Kalhor, Stephen G. Swisher, George R. Simon, David J. Stewart, J. Jack Lee, Ignacio I. Wistuba
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (23): 6556–6565.
https://doi.org/10.1158/1078-0432.CCR-12-3946
Published: 01 December 2013
View article titled, EZH2 Protein Expression Associates with the Early Pathogenesis, Tumor Progression, and Prognosis of Non–Small Cell Lung Carcinoma
Open the PDF for EZH2 Protein Expression Associates with the Early Pathogenesis, Tumor Progression, and Prognosis of Non–Small Cell Lung Carcinoma in another window
Includes: Supplementary data
Journal Articles

Outcomes of Phase II Clinical Trials with Single-Agent Therapies in Advanced/Metastatic Non–Small Cell Lung Cancer Published between 2000 and 2009

Filip Janku, Donald A. Berry, Jing Gong, Henrique A. Parsons, David J. Stewart, Razelle Kurzrock
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (22): 6356–6363.
https://doi.org/10.1158/1078-0432.CCR-12-0178
Published: 14 November 2012
View article titled, Outcomes of Phase II Clinical Trials with Single-Agent Therapies in Advanced/Metastatic Non–Small Cell Lung Cancer Published between 2000 and 2009
Open the PDF for Outcomes of Phase II Clinical Trials with Single-Agent Therapies in Advanced/Metastatic Non–Small Cell Lung Cancer Published between 2000 and 2009 in another window
Includes: Supplementary data
Journal Articles

Abstract A21: Tissue platinum concentration and tumor response in non-small cell lung cancer

Eric S. Kim, Guangan He, Chi-Wan Chow, Junya Fujimoto, Jack J. Lee, Neda Kalhor, Stephen G. Swisher, Ignacio I. Wistuba, David J. Stewart, Zahid H. Siddik
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (3_Supplement): A21.
https://doi.org/10.1158/1078-0432.12AACRIASLC-A21
Published: 01 February 2012
View article titled, Abstract A21: Tissue platinum concentration and tumor response in non-small cell lung cancer
Open the PDF for Abstract A21: Tissue platinum concentration and tumor response in non-small cell lung cancer in another window
Journal Articles

Translating Clinical Trials into Meaningful Outcomes

Patricia M. LoRusso, Lowell E. Schnipper, David J. Stewart, Scott A. Boerner, Steven D. Averbuch, Walter Wolf
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (24): 5951–5955.
https://doi.org/10.1158/1078-0432.CCR-10-2632
Published: 16 December 2010
View article titled, Translating Clinical Trials into Meaningful Outcomes
Open the PDF for Translating Clinical Trials into Meaningful Outcomes in another window
Journal Articles

Nrf2 and Keap1 Abnormalities in Non–Small Cell Lung Carcinoma and Association with Clinicopathologic Features

Luisa M. Solis, Carmen Behrens, Wenli Dong, Milind Suraokar, Natalie C. Ozburn, Cesar A. Moran, Alejandro H. Corvalan, Shyam Biswal, Stephen G. Swisher, B. Nebiyou Bekele, John D. Minna, David J. Stewart, Ignacio I. Wistuba
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (14): 3743–3753.
https://doi.org/10.1158/1078-0432.CCR-09-3352
Published: 14 July 2010
View article titled, Nrf2 and Keap1 Abnormalities in Non–Small Cell Lung Carcinoma and Association with Clinicopathologic Features
Open the PDF for Nrf2 and Keap1 Abnormalities in Non–Small Cell Lung Carcinoma and Association with Clinicopathologic Features in another window
Includes: Supplementary data
Journal Articles

Decitabine Effect on Tumor Global DNA Methylation and Other Parameters in a Phase I Trial in Refractory Solid Tumors and Lymphomas

David J. Stewart, Jean-Pierre Issa, Razelle Kurzrock, Maria I. Nunez, Jaroslav Jelinek, David Hong, Yasuhiro Oki, Zhong Guo, Sanjay Gupta, Ignacio I. Wistuba
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (11): 3881–3888.
https://doi.org/10.1158/1078-0432.CCR-08-2196
Published: 01 June 2009
View article titled, Decitabine Effect on Tumor Global DNA Methylation and Other Parameters in a Phase I Trial in Refractory Solid Tumors and Lymphomas
Open the PDF for Decitabine Effect on Tumor Global DNA Methylation and Other Parameters in a Phase I Trial in Refractory Solid Tumors and Lymphomas in another window
Journal Articles

Genetic Variants in Cell Cycle Control Pathway Confer Susceptibility to Lung Cancer

Wei Wang, Margaret R. Spitz, Hushan Yang, Charles Lu, David J. Stewart, Xifeng Wu
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (19): 5974–5981.
https://doi.org/10.1158/1078-0432.CCR-07-0113
Published: 01 October 2007
View article titled, Genetic Variants in Cell Cycle Control Pathway Confer Susceptibility to Lung Cancer
Open the PDF for Genetic Variants in Cell Cycle Control Pathway Confer Susceptibility to Lung Cancer in another window
Journal Articles

A Multicenter Phase II Trial of Losoxantrone (DuP-941) in Hormone-refractory Metastatic Prostate Cancer

Susan D. Huan, Ronald B. Natale, David J. Stewart, George P. Sartiano, Philip J. Stella, John D. Roberts, Aston L. Symes, Michael Finizio
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (4): 1333–1336.
Published: 01 April 2000
View article titled, A Multicenter Phase II Trial of Losoxantrone (DuP-941) in Hormone-refractory Metastatic Prostate Cancer
Open the PDF for A Multicenter Phase II Trial of Losoxantrone (DuP-941) in Hormone-refractory Metastatic Prostate Cancer in another window